Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

“Our software updates reflect the needs our customers communicate to us, and GastroPlus 9.9 is no exception,” said Neil Miller, Vice President of Simulation Sciences at Simulations Plus. “We ...

Shawn O'Connor, Chief Executive Officer, stated that "we delivered on the first quarter top line guidance we communicated in December, with revenue decreasing 3% as expected. Adjusted EBITDA was $3.5 ...

Pharmaceutical industry software developer Simulations Plus Inc. on Tuesday said it signed an agreement to sell its wholly owned Words+ subsidiary to an Ohio company for $2.1 million. Words+ is a ...

CEO Shawn O’Connor highlighted a 23% year-over-year revenue increase, with 5% organic growth, driven by the Adaptive Learning & Insights (ALI) and Medical Communication (MC) business units. Adjusted ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that ...

Webcast links will be available on the Investor Relations section of our website. For more information about the events or questions about registration, interested parties should reach out to their ...

Simulations Plus (NASDAQ:SLP) will release its quarterly earnings report on Monday, 2025-12-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Simulations Plus to ...